Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001) - Trial NCT05891821
Access comprehensive clinical trial information for NCT05891821 through Pure Global AI's free database. This Phase 2 trial is sponsored by Immune Oncology Research Institute and is currently Not yet recruiting. The study focuses on Lymphoma. Target enrollment is 20 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Immune Oncology Research Institute
Timeline & Enrollment
Phase 2
Jun 01, 2023
Jun 01, 2029
Primary Outcome
Objective Response Rate (ORR)
Summary
The goal of this study is to see if the drug balstilimab is safe and effective in
 participants with relapsed/refractory lymphomas.
 
 Participants will receive balstilimab every 3 weeks and their outcomes will be assessed
 periodically.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05891821
Non-Device Trial